Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Subgroup Analyses Show Depth of Everolimus Benefit in BOLERO-2

November 15th 2013

New analyses of the BOLERO-2 trial found that everolimus and exemestane produced significantly longer progression-free survival than placebo and exemestane in several previously unstudied patient subgroups.

Dr. Shulman on the CALGB 40101 Trial

November 13th 2013

Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses the results of the CALGB 40101 trial.

Breast Cancer Patients Prefer Subcutaneous Trastuzumab

November 12th 2013

Women with HER2-positive early breast cancer favor subcutaneous over intravenous (IV) administration of trastuzumab (Herceptin).

Dr. Nielsen Discusses the PAM50 Assay

November 8th 2013

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.

Managing mTOR Inhibitor Side Effects in Breast Cancer

November 4th 2013

Selecting the optimal treatment for postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer (MBC) remains a challenge, given a preponderance of data for several approved therapeutics

Dr. Liu Describes the CellSearch CTC Test

October 31st 2013

Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, describes the CellSearch CTC Test in breast cancer.

Dr. Michael Gnant on the PAM50 Breast Cancer Intrinsic Subtypes

October 27th 2013

Michael Gnant, MD, professor of the Department of Surgery at the Medical University of Vienna in Vienna, Austria, discusses the four intrinsic subtypes of the PAM50 recurrence score test and a clinical trial comparing this test with OncotypeDX.

Perioperative Breast MRI Does Not Lower Recurrence Risk for Early-Stage Patients

October 24th 2013

Patients with DCIS who received an MRI added to mammography before or immediately after receiving a lumpectomy did not experience an improvement in the rate of disease recurrence

Suzanne Fuqua on Biopsying Metastatic Tumors

October 18th 2013

Suzanne A. W. Fuqua, PhD, professor of medicine, Baylor College of Medicine, says that it is an exciting time for the treatment of patients with metastatic breast cancer.

Dr. Hudis on Promising Treatment Strategies in TNBC

October 17th 2013

Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, attending physician, Memorial Sloan-Kettering Cancer Center, discusses the challenges and recent advancements of treating patients with triple-negative breast cancer.

Dr. Debu Tripathy on Integrative Oncology

October 15th 2013

Debu Tripathy, MD, co-leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, discusses integrative oncology

A Leader in Both Research and Practice

October 15th 2013

Few of ASCO's past presidents were faced with the multitude of challenges that arose during the presidency of Sandra M. Swain, MD, who is medical director of the Washington Cancer Institute at Medstar Washington Hospital Center and a professor of Medicine at Georgetown University, and is currently ASCO's immediate past president.

Dr. Rugo on Metastatic Breast Cancer Guidelines

October 11th 2013

Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses new guidelines for the treatment of patients with metastatic breast cancer.

Precision Cancer Medicine: New Era for Translating Lab Research Is Emerging

October 8th 2013

It is well recognized that advances in cancer management have most often resulted from a close collaboration between clinical and laboratory investigative efforts.

New ASCO/CAP Guideline Enhances HER2 Testing in Breast Cancer

October 7th 2013

The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) have released updated recommendations for HER2 testing in breast cancer.

Dr. Zujewski Discusses Breast Cancer Drug Development

October 3rd 2013

Jo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute (NCI), discusses the development of drugs to treat patients with breast cancer.

Dr. Hudis on BOLERO-3 Trial Biomarker Observations

October 1st 2013

Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, attending physician, Memorial Sloan-Kettering Cancer Center, comments on exploratory biomarker observations from the BOLERO-3 trial.

Dual HER2 Blockade Less Effective in PI3KCA-Mutant Breast Cancer

October 1st 2013

Breast cancer patients with PI3KCA mutations are less likely to achieve a pathological complete response from dual HER2 blockade in the neoadjuvant setting.

FDA Approves Neoadjuvant Pertuzumab Regimen

September 30th 2013

Pertuzumab in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer

BOLERO-3 Biomarker Study Provides Clues for Response to Everolimus

September 30th 2013

Exploratory analysis of biomarkers in the BOLERO-3 trial suggests that the addition of everolimus to trastuzumab plus vinorelbine for HER2-positive advanced breast cancer may be most beneficial in patients with low PTEN or high pS6 levels.